"We are now finally in
a position to deliver our therapies to the large numbers of people who suffer
vision loss as a result of neurological brain damage as a cost effective and
complete therapy solution" - CEO of Vycor
BOCA RATON, Florida - June 25, 2015
(Investorideas.com Newswire) - Vycor Medical, Inc. ("Vycor") (VYCO), a provider of innovative and superior surgical and therapeutic
solutions, announced the commercial release of its Internet-delivered therapy
suite in the U.S. This therapy suite, consisting of its lead Vision Restoration
Therapy (VRT) and its NeuroEyeCoach eye-movement compensation therapy, is
delivered directly to patients over the Internet onto their own computers replacing
the Company's current "prototype hardware centric" model.
NovaVision has been working to take its VRT therapy
prototype and develop it into an affordable, scalable therapy offering that
offers broader patient benefits. VRT will going forward be provided alongside
NovaVision's NeuroEyeCoach compensatory therapy in one Internet delivered
therapy suite. Two things happen when someone suffers from vision related
disorders following a stroke or brain injury: there is a loss of visual field
as well as difficulty with eye movement, affecting the ability to integrate
visual information. VRT addresses the restoration of lost vision while
NeuroEyeCoach addresses patients' difficulty with their eye movements and their
ability to integrate visual information, allowing them to make the most of
their remaining vision, The two therapies provided in a suite are therefore
highly complementary and ensure broad benefits to NovaVision's patients.
NovaVision is now positioned, for the first time,
with the suite of therapies and product offerings to deliver on its strategic
vision: to provide a clinically supported, affordable and scalable visual
therapy solution offering broad benefits to those suffering visual impairment
following neurological damage; and to offer solutions for both patients and
physicians alike.
For Patients:
·
VRT and NeuroEyeCoach
Therapy Suite. NovaVision will commercially launch this week
these two complementary therapies, internet-delivered in a package for $900.
·
NeuroEyeCoach. For patients with visual impairments who are not suitable, for
whatever reason, for VRT, NovaVision provides NeuroEyeCoach on its own for
$450.
For Physicians:
·
Vision Diagnostic (VIDIT). The diagnostic component of VRT that enables therapists to perform
high-resolution visual field tests in less than 10 minutes to screen for visual
field deficits.
·
NeuroEyeCoach Pro Center. Enables stroke rehabilitation and other centers to treat patients
while in their care, both as in-patient and out-patient.
·
NovaVision and NeuroEyeCoach
Pro Physician. Enables physicians to register patients in
their clinic who complete the therapy at home, supported by NovaVision but
monitored by the physician through a dedicated portal.
VRT is a prescription product and the only FDA cleared
therapy (510k) for the restoration of vision loss from neurological damage. VRT
is supported by 15 years of clinical research and over 20 studies including a
302 patient study in which notable improvements were seen in 70% of the
patients. NeuroEyeCoach is also clinically supported being based on research
that has been the subject of 14 clinical studies on a total of 591 patients and
has FDA registration.
Commenting on the Company's announcement, Peter
Zachariou, CEO of Vycor, stated: "This has been a long time coming and has
entailed an enormous amount of work from both our employees but also our
scientific advisors and is a key milestone for NovaVision. We are now finally
in a position to deliver our therapies to the large numbers of people who suffer
vision loss as a result of neurological brain damage as a cost effective and
complete therapy solution. I am convinced that this new therapy suite is the
most robust, affordable and complete commercially available visual therapy
solution targeted at this type of vision loss.
This also represents the final step in moving
NovaVision from being a development company to one focused on commercializing
its unique suite of products. I would urge anyone who has had a stroke or brain
injury and suffers from a visual disorder to contact us, we have numerous
testimonials of patients for whom these therapies have literally changed their
lives".
There are approximately 8m stroke survivors in the
U.S. with 795,000 strokes a year, and approximately 1.5m suffering some sort of
Traumatic Brain Injury (TBI) annually; up to 30% of these suffer a resultant
visual impairment, up to 20% permanently. In all, around 2.8 million Americans
suffer from this type of vision impairment, which is largely unaddressed by the
rehabilitation system. The impact on their daily lives is dramatic, and is the
difference between a person being able to be home alone, cross the road
unaided, drive, shop or read. The new therapy suite is targeted at this largely
underserved group of people.
About Vycor Medical, Inc.
With corporate headquarters in Boca Raton, FL,
Vycor Medical, Inc. ("Vycor") is a publicly traded company (VYCO)
dedicated to providing the medical community with innovative and superior
surgical and therapeutic solutions and has a growing portfolio of FDA cleared
medical solutions that are changing and improving lives every day. The Company
operates two business units: Vycor Medical and NovaVision, both of which adopt
a minimally or non-invasive approach. Both technologies have exceptional sales
growth potential, address large potential markets, have the requisite
regulatory approvals and are commercialized and generating revenue.
Vycor Medical's ViewSite(TM) Surgical Access
Systems (VBAS) is a suite of clear cylindrical minimally invasive disposable
devices that hold the potential for speedier, safer and more economical brain
surgeries and a quicker patient discharge. VBAS is designed to optimize
neurosurgical site access, reduce patient risk, accelerate recovery and add
tangible value to the professional medical community. The company is ISO
13485:2003 compliant, has U.S. FDA 510(k) clearance for brain and spine
surgeries and full regulatory approvals for brain in Australia, Canada, China,
Europe (EU - Class III), Korea and Japan and is seeking or has partial
regulatory approvals in Brazil, India, Russia, Taiwan and Vietnam. For an
overview of Vycor Medical's VBAS see VBAS Video.
NovaVision develops and provides science-driven
neurostimulation therapy and other medical technologies that help improve and
partially restore sight in patients with neurological vision impairments. The
company's proprietary Visual Restoration Therapy(R) (VRT) platform is
clinically supported to improve lost vision resulting from stroke, traumatic
brain injury (“TBI”), or other acquired brain injuries. VRT is the only FDA
510K cleared medical device in the U.S. aimed at the restoration of vision for
neurologically induced vision loss and can be prescribed by any Physician. VRT
also has CE Marking for the EU. NovaVision also provides Neuro Eye Therapy
(NeET) in the EU, aimed at increasing visual sensitivity deep within the field
defect.
The Company has also developed a therapy called
NeuroEyeCoach(TM). The NeuroEyeCoach(TM) therapy is highly complementary to
VRT(TM). The two therapies address different visual disabilities each of which
results from neurologically-induced vision loss - a loss of visual field as
well as difficulty with eye movement, affecting the ability to integrate visual
information. VRT provides partial restoration of the patient’s lost visual
field; NeuroEyeCoach(TM) is designed to increase the efficiency of eye movement
and re-train the patients’ ability to integrate visual information between the
left and right hand side. For an overview of NovaVision see NovaVision Video.
Safe Harbor Statement
Information in this document constitute
forward-looking statements or statements which may be deemed or construed to be
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. The words "forecast", "anticipate",
"estimate", "project", "intend",
"expect", "should", "believe", and similar
expressions are intended to identify forward-looking statements. These
forward-looking statements involve, and are subject to known and unknown risks,
uncertainties and other factors which could cause Vycor Medical's actual
results, performance (financial or operating) or achievements to differ from
the future results, performance (financial or operating) or achievements
expressed or implied by such forward-looking statements. The risks,
uncertainties and other factors are more fully discussed in Vycor Medical’s
filings with the U.S. Securities and Exchange Commission. All forward-looking
statements attributable to Vycor Medical herein are expressly qualified in
their entirety by the above-mentioned cautionary statement. Vycor Medical
disclaims any obligation to update forward-looking statements contained in this
estimate, except as may be required by law.
Vycor Medical, Inc. Contacts:
SOURCE: Vycor Medical, Inc.
Disclaimer/Disclosure: The Investorideas.com newswire is a third party publisher of news
as well as creates original content as a news source. Original content created
by investor ideas is protected by copyright laws other than syndication rights.
Investorideas is a news source on Google news and global syndication partners.
Our site does not make recommendations for purchases or sale of stocks or
products. Nothing on our sites should be construed as an offer or solicitation
to buy or sell products or securities. All investment involves risk and
possible loss of investment. This site is currently compensated by featured
companies, news submissions and advertising. Contact each company directly for
press release questions. Disclosure is posted on each release if required but
otherwise the news was not compensated for and is published for the sole
interest of our readers. Vycor Medical Inc. (VYCO): June 2, 2015 – The company
has retained Investor Ideas for PR, media and news distribution: Five thousand
per month, one month with option to renew.
BC Residents and Investor Disclaimer: Effective
September 15 2008 - all BC investors should review all OTC and Pink sheet
listed companies for adherence in new disclosure filings and filing appropriate
documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.
